Impact of colorectal cancer screening participation in remote northern Canada: A retrospective cohort study

Table 2 Screen detected vs clinically detected cancer, 2014-2016

Baseline characteristics	Screen detected (n = 19)	Clinically detected (n = 34)	P value
Age, mean years (SD)	63.2 (7.47)	59.1 (7.27)	0.061
Sex, female (%; Std. Res)	6 (31.58; -0.56)	15 (68.42; 0.45)	0.37
Indigenous (%; Std. Res)	11 (33.33; -0.24)	22 (66.66; 0.18)	0.62
Region of residence (%; Std. Res)			0.892
Beaufort Delta	< 5 (21.05; -0.31)	9 (26.47; 0.23)
Dehcho	N/A	N/A
Fort Smith	< 5 (5.26; -0.59)	< 5 (11.76; 0.44)
Hay River	< 5 (15.79; 0.31)	< 5 (11.76; -0.23)
Sahtu	< 5 (0; -0.85)	< 5 (5.88; 0.63)
Tilcho	< 5 (10.53; 0.16)	< 5 (8.82; -0.12)
Yellowknife	9 (47.37; 0.54)	12 (35.29; -0.40)
Histology type, n (%; Std. Res)			0.132
Adenocarcinoma	18 (94.74; 0.37)	28 (82.35; -0.28)
Carcinoid	< 5 (5.26; 1.07)	< 5 (0; -0.80)
Mucinous	< 5 (0; -0.85)	< 5 (5.88; 0.63)
Other	< 5 (0; -1.20)	< 5 (11.76; 0.90)
Location, n (%; Std. Res)			0.252
Proximal	< 5 (10.53; -1.23)	11 (32.35; 0.92)
Distal	17 (89.47; 0.70)	23 (67.65; -0.53)
Stage, n (%; Std. Res)			0.18
Early	12 (63.16; 0.75)	15 (44.12; -0.56)
Late	7 (36.83; -0.76)	19 (55.88; 0.57)

¹Mann-Whitney-Wilcoxon Test.

²Fisher’s Exact Test for Count Data. Std. Res: Standardized residual. N/A: Not applicable.